Recombinant Human Annexin A3 (ANXA3) Protein (His)

Name: Recombinant Human Annexin A3 (ANXA3) Protein (His)
Brand: Beta LifeScience
SKU: BLC-03537P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Collections: High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Annexin A3 (ANXA3) Protein (His) is produced by our E.coli expression system. This is a protein fragment.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	P12429
Target Symbol	ANXA3
Synonyms	2-cyclic phosphate 2-phosphohydrolase; 35-alpha calcimedin; Annexin A3; Annexin III; Annexin-3; ANX3; ANXA 3; Anxa3; ANXA3_HUMAN; Calcimedin 35 alpha; Inositol 1 2 cyclic phosphate 2 phosphohydrolase ; Inositol 1; Lipocortin III; OTTHUMP00000160701; OTTHUMP00000219237; OTTHUMP00000219238; PAP III; PAP-III; Placental anticoagulant protein III
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-6His
Target Protein Sequence	WVGHRGTVRDYPDFSPSVDAEAIQKAIRGIGTDEKMLISILTERSNAQRQLIVKEYQAAYGKELKDDLKGDLSGHFEHLMVALVTPPAVFDAKQLKKSMKGAGTNEDALIEILTTRTSRQMKDISQAYYTVYKKSLGDDISSETSGDFRKALLTLADGRRDESLKVDEHLAKQDAQILYKAGENRWGTDEDKFTEILCLRSFPQLKLTFDEYRNISQKDIVDSIKGELSGHFEDLLLAIVNCVRNTPAFLAERLHRALKGIGTDEFTLNRIMVSRSEIDLLDIRTEFKKHYGYSLYSAIKSDTSGDYEITLLKICGGD
Expression Range	5-322aa
Protein Length	Partial
Mol. Weight	39.9kDa
Research Area	Signal Transduction
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Inhibitor of phospholipase A2, also possesses anti-coagulant properties. Also cleaves the cyclic bond of inositol 1,2-cyclic phosphate to form inositol 1-phosphate.
Protein Families	Annexin family
Database References	HGNC: 541 OMIM: 106490 KEGG: hsa:306 STRING: 9606.ENSP00000264908 UniGene: PMID: 28703915 The down-regulation of Annexin A3 by siRNA inhibited the invasion and epithelial-mesenchymal transition of colorectal cancer cells through the up-regulation of p53. PMID: 29224019 ANXA3 plays important roles in gastric cancer carcinogenesis and metastasis. PMID: 27894078 The findings implicate the expression of ANXA3 with the natural progression of breast cancer and associate it with increased lymphatic metastasis. The study validates the use of ANXA3 as a potential prognosis biomarker for breast cancer. PMID: 28497041 we identified ANXA3 as a regulator of hepatitis C virus maturation and egress PMID: 27653686 ANXA3 role in the proliferation and invasion of breast cancer cells. PMID: 27878264 Results identified potential variant in ANXA3 gene [chr4, c.C820T(p.R274*)] in a large family with an unknown equinus deformity, which could lead to a three-dimensional conformational change. PMID: 27475959 Anxa3 knockdown inhibited the growth, migration, invasion, and metastasis of lung adenocarcinoma. PMID: 27995049 These results suggest that the iEA index or a combination of polymorphisms in EGFR and ANXA3 may serve as predictive factors of drug response, and therefore could be useful for optimal selection of chemotherapy regimens. PMID: 26475168 ANX A3 has roles as a mammary biomarker, regulator and therapeutic target in breast cancer PMID: 26093083 Our results suggest that ANXA3 can serve as a novel diagnostic biomarker and that the inhibition of ANXA3 may be a viable therapeutic option for the treatment of CD133+ liver-CSC-driven HCC. PMID: 26095609 Findings reveal that ANXA3 might play an important role in hepatocellular carcinoma progression and chemoresistance. PMID: 24375474 findings suggest that ANXA3 plays a role in HCC CSC/CIC maintenance, and that ANXA3 may represent a potential CSC/CIC-specific therapeutic target for improving the treatment of HCC. PMID: 25267273 Two different antigenic variants of ANXA3 are present in post-DRE urines and their clinical significance for diagnosis of prostate cancer should be further investigated. PMID: 24954692 Expression of annexin A3 was increased in gastric cancer compared with that in normal gastric tissues. Annexin A3 expression was significantly associated with tumor volume and TNM stage. PMID: 24815437 Annexin A3 was upregulated in gastric cancer cells. Deletion of endogenous Annexin A3 significantly inhibited gastric cancer cell proliferation, migration, and invasion. PMID: 24824926 Low ANXA3 expression is associated with radioresistance in nasopharyngeal carcinoma. PMID: 23464856 Annexin A3 expression correlates with tumor size and lymph node metastasis.Annexin A3 might be regulated apoptosis by affecting Bcl-2/Bax balance.Annexin A3 was an independent prognostic factor in breast cancer. PMID: 23631820 The expression change of Anxa3 can be utilized as a potential indicator for the development, invasion, metastasis and drug resistance of tumors. PMID: 23011854 the association of multi-drug resistance with ANXA3, one of the highly expressed proteins in BEL7402/5-FU-resistant hepatoma cell line, was verified PMID: 22189913 annexin A3 secretion may be associated with exocytosis and the release of exosomes PMID: 21435174 Decreased expression of ANXA3 in papillary thyroid cancer supports the idea that ANXA3 may be an effective marker of microcarcinoma, and a negative predictor of papillary thyroid cancer progression. PMID: 21137070 AnnexinA3 plays an important role in the initiation and progression of human gallbladder cancer. PMID: 21055154 two spliced isoforms of Annexin A3 are expressed differently in human renal cortex and renal-cell carcinoma PMID: 20167856 Annexin A3 could be a target for therapeutic intervention and may also serve as a biomarker for drug resistance in ovarian cancer patients. PMID: 20103635 ANXA3 is a novel angiogenic factor that induces vascular endothelial growth factor production through the hypoxia-inducible factor-1 pathway PMID: 16236264

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.